Breaking News Instant updates and real-time market news.

HALO

Halozyme

$14.46

-0.53 (-3.54%)

08:01
12/19/18
12/19
08:01
12/19/18
08:01

Halozyme announces insider purchases of C$135,000

Halo Labs announced that over the past several weeks, management and members of the board have purchased shares of Halo Labs on the open market. Halo CEO, Kiran Sidhu, purchased a total of 347,500 shares of Halo in the period from November 30th, 2018 to date on the open market for an average price of approximately C$0.2882 per share totalling C$100,162, bringing his total ownership to 3,468,352 shares. Halo Chairman, Scott Paterson, purchased a total of 100,000 shares of Halo on October 5th, 2018 on the open market for an average price of approximately C$0.35 per share totalling C$35,000 and bringing his total ownership to 3,791,116 shares.

HALO Halozyme
$14.46

-0.53 (-3.54%)

11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
11/27/18
JEFF
11/27/18
NO CHANGE
Target $9
JEFF
Underperform
Jefferies still sees low likelihood of success for Halozyme's PEGPH20
Following the announced change in the Phase 3 endpoint, Jefferies analyst Eun Yang continues to view probability for success of Halozyme Therapeutics's PEGPH20 in pancreatic cancer as low. The change in the HALO-301 endpoint/data analysis "dampens our confidence further," Yang tells investors in a research note. HALO-301 is a phase 3 global, randomized, double-blind placebo controlled clinical trial evaluating investigational new drug PEGPH20 as a first-line therapy for potential treatment of patients with metastatic pancreas cancer. The analyst remains cautious on Halozyme shares with an Underpeform rating and $9 price target.
11/27/18
CANT
11/27/18
NO CHANGE
Target $27
CANT
Overweight
Halozyme modified Phase 3 design 'a good thing,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating and $27 price target on Halozyme Therapeutics after the company announced that it has made a request to the FDA to change the dual primary endpoints of progression free survival and overall survival of the HALO-301 study to the single primary endpoint of overall survival. On the surface, this "change" can quickly lead to a negative perception of trial progress, Duncan tells investors in a research note titled "Don't Miss the Forest for the Trees - Modified P3 is a Good Thing." However, when assessing the design and rationale, in conjunction with the study remaining blinded, the analyst views the move as "prudent, with the clinical risk thus having been reduced, at least, incrementally." He believes investors appreciate the high-risk in pancreatic cancer, and therefore see low expectations for Phase 3 success being priced into the current share price. Duncan says he has "enhanced non-zero conviction" in the potential for HALO-301 to read out positively in the second half of 2019.
10/18/18
PIPR
10/18/18
INITIATION
Target $17
PIPR
Neutral
Halozyme assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro assumed coverage of Halozyme Therapeutics with a Neutral rating and $17 price target. While the analyst views the Enhanze technology as an "attractive platform that could drive substantial royalty revenue," he has near term concerns around the pivotal HALO-301 study. He believes HALO-301 will need to hit on both progression-free survival and overall survival to support approval and adoption, which tempers his expectations.

TODAY'S FREE FLY STORIES

EMR

Emerson

$67.03

-0.18 (-0.27%)

09:51
10/15/19
10/15
09:51
10/15/19
09:51
Hot Stocks
Breaking Hot Stocks news story on Emerson »

D.E. Shaw calls for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

TNDM

TNDM

, ABT

Abbott

$81.63

1.82 (2.28%)

09:50
10/15/19
10/15
09:50
10/15/19
09:50
Recommendations
TNDM, Abbott, DexCom, Insulet analyst commentary  »

Abbott partnership a…

TNDM

TNDM

ABT

Abbott

$81.63

1.82 (2.28%)

DXCM

DexCom

$153.56

-6.64 (-4.14%)

PODD

Insulet

$154.02

1.72 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

AMBA

Ambarella

$56.30

3.19 (6.01%)

09:50
10/15/19
10/15
09:50
10/15/19
09:50
Recommendations
Ambarella analyst commentary  »

KeyBanc boosts Ambarella…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

09:50
10/15/19
10/15
09:50
10/15/19
09:50
General news
IMF's global growth outlooks were trimmed »

IMF's global growth…

NR

Newpark Resources

$6.77

-0.155 (-2.24%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
Newpark Resources falls -5.3% »

Newpark Resources is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

MTW

Manitowoc

$10.71

-0.68 (-5.97%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
Manitowoc falls -5.9% »

Manitowoc is down -5.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$40.25

-6 (-12.97%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
PagSeguro Digital falls -13.7% »

PagSeguro Digital is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

  • 17

    Dec

  • 17

    Oct

UNH

UnitedHealth

$233.30

12.98 (5.89%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
UnitedHealth rises 5.7% »

UnitedHealth is up 5.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

FRC

First Republic

$103.44

6.08 (6.24%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
First Republic rises 6.0% »

First Republic is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

APHA

Aphria

$5.39

1.06 (24.48%)

09:47
10/15/19
10/15
09:47
10/15/19
09:47
Hot Stocks
Aphria rises 21.8% »

Aphria is up 21.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 12

    Nov

TBPH

Theravance Biopharma

$17.25

(0.00%)

09:45
10/15/19
10/15
09:45
10/15/19
09:45
Syndicate
Theravance Biopharma 5.7M share Block Trade priced at $17.50 »

Woodford Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BYSI

BeyondSpring

$18.08

(0.00%)

09:44
10/15/19
10/15
09:44
10/15/19
09:44
Syndicate
Breaking Syndicate news story on BeyondSpring »

BeyondSpring files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

EMR

Emerson

$67.21

(0.00%)

09:43
10/15/19
10/15
09:43
10/15/19
09:43
Periodicals
D.E. Shaw report calling for Emerson split coming today, CNBC reports »

D.E. Shaw has over a 1%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

STLD

Steel Dynamics

$29.64

(0.00%)

, IGT

International Game

$14.02

(0.00%)

09:40
10/15/19
10/15
09:40
10/15/19
09:40
Options
Unusually active option classes on open October 15th »

Unusual total active…

STLD

Steel Dynamics

$29.64

(0.00%)

IGT

International Game

$14.02

(0.00%)

JPM

JPMorgan

$116.39

(0.00%)

UNH

UnitedHealth

$220.32

(0.00%)

GS

Goldman Sachs

$205.81

(0.00%)

NVDA

Nvidia

$186.51

(0.00%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.83

(0.00%)

C

Citi

$70.28

(0.00%)

WLL

Whiting Petroleum

$7.26

(0.00%)

SCHW

Charles Schwab

$37.74

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 17

    Oct

  • 18

    Oct

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 12

    Nov

  • 20

    Nov

CPIX

Cumberland

$5.59

-0.05 (-0.89%)

09:38
10/15/19
10/15
09:38
10/15/19
09:38
Hot Stocks
Cumberland: Study shows Vibativ superiority in some bacterial pneumonia patients »

Cumberland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMR

Emerson

$67.21

0.16 (0.24%)

09:37
10/15/19
10/15
09:37
10/15/19
09:37
Periodicals
Breaking Periodicals news story on Emerson »

D.E. Shaw to call for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

IAC

IAC

$226.69

-0.5 (-0.22%)

, MTCH

Match Group

$74.00

-0.12 (-0.16%)

09:34
10/15/19
10/15
09:34
10/15/19
09:34
Conference/Events
Cowen US internet/media analyst to hold analyst/industry conference call »

U.S. Internet & Media…

IAC

IAC

$226.69

-0.5 (-0.22%)

MTCH

Match Group

$74.00

-0.12 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.28

-0.14 (-3.17%)

09:31
10/15/19
10/15
09:31
10/15/19
09:31
Downgrade
Encana rating change  »

Encana downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

WLL

Whiting Petroleum

09:31
10/15/19
10/15
09:31
10/15/19
09:31
Downgrade
Whiting Petroleum rating change  »

Whiting Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

OAS

Oasis Petroleum

$3.11

-0.135 (-4.17%)

09:31
10/15/19
10/15
09:31
10/15/19
09:31
Downgrade
Oasis Petroleum rating change  »

Oasis Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBL

Noble Energy

$20.44

-0.15 (-0.73%)

09:31
10/15/19
10/15
09:31
10/15/19
09:31
Upgrade
Noble Energy rating change  »

Noble Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

PH

Parker-Hannifin

$178.45

-1.25 (-0.70%)

09:30
10/15/19
10/15
09:30
10/15/19
09:30
Recommendations
Parker-Hannifin analyst commentary  »

Parker-Hannifin sales,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

WHD

Cactus

$28.03

-0.49 (-1.72%)

, HAL

Halliburton

$18.75

-0.195 (-1.03%)

09:30
10/15/19
10/15
09:30
10/15/19
09:30
Recommendations
Cactus, Halliburton, National Oilwell, Newpark Resources, Nine Energy Services, Oil States, Patterson-UTI, Unit Corp., USA Compression analyst commentary  »

Raymond James sees…

WHD

Cactus

$28.03

-0.49 (-1.72%)

HAL

Halliburton

$18.75

-0.195 (-1.03%)

NOV

National Oilwell

$21.10

-0.08 (-0.38%)

NR

Newpark Resources

$6.93

-0.655 (-8.64%)

NINE

Nine Energy Services

$5.16

-0.24 (-4.44%)

OIS

Oil States

$12.93

-0.065 (-0.50%)

PTEN

Patterson-UTI

$8.15

-0.1 (-1.21%)

UNT

Unit Corp.

$2.83

-0.165 (-5.52%)

USAC

USA Compression

$17.40

0.225 (1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 29

    Oct

  • 31

    Oct

  • 11

    Nov

  • 13

    Nov

JNJ

Johnson & Johnson

$130.67

-0.68 (-0.52%)

09:28
10/15/19
10/15
09:28
10/15/19
09:28
Hot Stocks
Johnson & Johnson says will continue to consider 'opportunistic acquisitions' »

Says: Q3 was a good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

IMO

Imperial Oil

$24.25

-0.235 (-0.96%)

09:27
10/15/19
10/15
09:27
10/15/19
09:27
Upgrade
Imperial Oil rating change  »

Imperial Oil upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.